Glenmark Pharmaceuticals Recalls Theophylline Tablets Over Dissolution Issues
Glenmark Pharmaceuticals Inc. recalled 22,656 bottles of Theophylline extended-release tablets on August 8, 2025. The recall follows reports of failed dissolution specifications that could impact medication efficacy. Consumers should stop using the product and consult healthcare providers immediately.
Quick Facts at a Glance
Recall Date
August 8, 2025
Hazard Level
HIGH
Brands
Glenmark Pharmaceuticals Inc., THEOPHYLLINE
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL
Hazard Information
Failed Dissolution Specifications: Failure results (above) were reported for the Dissolution (by UV) test for commercial annual stability at the long-term shelf life stability interval, wherein the dissolution results do not comply with L3 stage dissolution criteria.
What You Should Do
Consumers and healthcare providers should stop using this product immediately. Contact Glenmark Pharmaceuticals Inc., USA or your healthcare provider for guidance. Notification method: Letter
Product Details
The recall affects Theophylline extended-release tablets, 400mg, in 100-count bottles. The products were manufactured by Glenmark Pharmaceuticals Limited in India and distributed nationwide in the USA.
The Hazard
The recall stems from failed dissolution specifications. The dissolution results did not comply with L3 stage criteria, potentially affecting the drug's effectiveness.
Reported Incidents
No injuries or adverse incidents have been reported associated with this recall. The potential for ineffective medication poses a serious health risk.
What to Do
Stop using the recalled Theophylline tablets immediately. Contact Glenmark Pharmaceuticals Inc. for further guidance and potential refund options.
Contact Information
Consumers can reach Glenmark Pharmaceuticals Inc. at their website for more information. For additional assistance, consult with healthcare providers.
Key Facts
Recall date: August 8, 2025
Distribution: USA nationwide
NDC: 68462-380-01
Potential health risks due to ineffective medication
Abiomed issued a recall for 10,153 Automated Impella Controllers on October 1, 2025. The devices face potential cybersecurity vulnerabilities related to their operating system. Healthcare providers and patients should stop using these devices immediately.
Acuity Specialty Products recalled its Wyandotte Sanifect E3 hand sanitizer on September 29, 2025. The recall affects multiple package configurations due to potential methanol contamination. Consumers should stop using the product immediately and contact the company for guidance.
AFCO recalled hand sanitizer on September 29, 2025, due to a risk of methanol contamination. The company failed to conduct required testing on incoming alcohol components. Consumers should stop using the product immediately.